The authors summarize currently approved tyrosine kinase inhibitors for HER2+ breast cancer, key clinical trials, and their use in current clinical practice.
[npj Breast Cancer]
Sorry, but the selected Zotpress account can't be found.
Sorry, but the selected Zotpress account can't be found.